Justin Dumouchel, MD
Pulmonary Disease · Oakland, CANPI 1508050212
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $326 of the $440 with a category attached, or 74.0%. 9 manufacturers reported payments, led by Olympus Corporation Of The Americas at 31.9% of the total. That places this record below the midpoint for pulmonary disease clinicians in CA, where the typical reported total is $1,248.
Across 17 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$141
- GSK$76
- Pulmonx Corporation$51
- Sanofi$39
- Insmed, Inc.$33
- Regeneron Healthcare Solutions, Inc.$29
- plus $71 from 3 others
What the payments were for
- Travel & lodging$11426%
- Food & beverage$32674%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 4 | $141 |
| GSK | 4 | $76 |
| Pulmonx Corporation | 2 | $51 |
| Sanofi | 2 | $39 |
| Insmed, Inc. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Abiomed | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$440 in reported general payments places this provider in the 35th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $1,133 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Oakland
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.